Marinomed licenses rights to antiviral product line for China

17-Jul-2013 - Austria
The rights to five medical products of the Viennese biotech company Marinomed have now been licensed to an international pharmaceutical company for the Chinese market. Besides three antiviral nasal sprays against common cold, influenza and colds in children, the deal also includes the two newest products from Marinomed: antiviral lozenges and a throat spray against viral throat infections. The entire product portfolio is based on the MAVIREX® technology platform from Marinomed. This takes advantage of special antiviral properties of a natural polymer derived from red algae.

In the light of this new partnership, Dr. Andreas Grassauer, CEO of Marinomed, said: "China is the third largest pharmaceuticals market in the world. Licensing our whole product portfolio here at one stroke is an important contribution towards our rapidly growing sales and distribution network. The experience and the presence of our partner in this market assure high efficiency."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances